

COVID-19 vaccines

謝思民

臺大醫院內科部感染科

In response to the pandemics of human infections due to SARS-CoV-2, many vaccine candidates from several platforms have been developed rapidly under rolling review process and EUA policy. Taiwan also has programs to establish and manufacture the protein-based Covid-19 vaccine to face the threat of pandemics, in addition to purchased adenovirus-vectored vaccines and mRNA vaccines. In this lecture, I will introduce the similarity between our domestic protein-based vaccine (MVC-COV1901) and Moderna mRNA vaccine, and up-to-date data and publication about the MVC-COV1901 vaccine. The rationale of the third dose of COVID-19 vaccines, the future of heterologous prime-boost policy, and the vaccine strategy to fight against emerging variants of concern will also be discussed.